Fimepinostat

Phase 1Small molecule

UUniversity of California, Los Angeles

Fimepinostat is one of 6 small molecule programs targeting Brain Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain TumorsActive, not recruiting

Brain TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Brain Tumors

#DrugCompanyPhaseTrials

Keppra

UCB

Phase 3

1 2

Lumakras

Amgen

Phase 1

1 3

Triostat

VViking Therapeutics, Inc.

Preclinical

1 4

Fimepinostat

UUniversity of California, Los Angeles

Phase 1

1 5

5-Aminolevulinic Acid

DDavid W. Roberts

Phase 1

1 6

NM404

UUniversity of Wisconsin, Madison

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Brain Tumors

NCT03893487

Q1 2029

Phase 2Recruiting

Cushing Disease

NCT05971758

Clinical

Trials by Indication[1]

Brain Tumors1 trial

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Active, not recruiting·SSabine Mueller, MD, PhD·Phase 1·NCT03893487·30 enrolled

Lymphoma1 trial

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Completed·CCuris, Inc.·Phase 1·NCT01742988·106 enrolled

Cushing Disease1 trial

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

Recruiting·UUniversity of California, Los Angeles·Phase 2·NCT05971758·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Fimepinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fimepinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fimepinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, Los Angeles

Fimepinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Trials by Indication[1]

Brain Tumors1 trial

Lymphoma1 trial

Cushing Disease1 trial

References

Drug Info

Quick Facts

Related News